BIOQUAL Announces Award of a Five Year AIDS Research Support Contract for $4.6M.Business Editors ROCKVILLE, Md.--(BUSINESS WIRE)--Dec. 19, 2000 On December 18, 2000, BIOQUAL, Inc. (OTC OTC See: Over-the-counter. OTC See over-the-counter market (OTC). :BIOQ, Chicago Stock Exchange Chicago Stock Exchange (CHX) A major exchange trading only stocks, with 90% of trades taking place on an automated execution system, called MAX. :BQI) renewed its contract to support AIDS researchers at the National Cancer Institute (NCI See Liberate. ) of the National Institutes of Health (NIH "Not invented here." See digispeak. NIH - The United States National Institutes of Health. ). The contract entitled "Nonhuman Primate Models of AIDS: Prophylactic and Therapeutic Studies" totals $4,628,783 and will operate for five years to December 2005. The contract supports research animals and assists NCI scientists in the evaluation of candidate HIV HIV (Human Immunodeficiency Virus), either of two closely related retroviruses that invade T-helper lymphocytes and are responsible for AIDS. There are two types of HIV: HIV-1 and HIV-2. HIV-1 is responsible for the vast majority of AIDS in the United States. and SIV vaccines, including the physiological and pathological consequences of vaccination, effects of various biological vector/recombinant adjuvant systems, and effects following live virus challenge in macaques, and studies the carcinogenic and genotoxic genotoxic /ge·no·tox·ic/ (je´no-tok?sik) damaging to DNA: pertaining to agents known to damage DNA, thereby causing mutations, which can result in cancer. ge·no·tox·ic adj. effects of antiretroviral therapy in the Patas monkey. Statements herein that are not descriptions of historical facts are forward-looking and subject to risk and uncertainties. Actual results could differ materially from those currently anticipated due to a number of factors including those set forth in BIOQUAL's Securities and Exchange Commission filings under "Risk Factors", including risks relating to the early stage of products under development; uncertainties relating to clinical trials; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of BIOQUAL's proposed products (such as marketing, safety, regulatory, patent, product liability, supply competition, and other risks). |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion